Oral Antiviral therapy for treatment of COVID-19 in Solid Organ Transplant Recipients: Is the Practice meeting the Promise? - 10/02/24
, Kenji Okumura 2, Seigo Nishida 2
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Solid organ transplant recipients (SOTRs) remain at high risk of progression to severe disease and hospitalization from Coronavirus disease 2019 (COVID-19). Regardless of vaccination status, burden of severe COVID-19 among SOTRs remains high and treatment of COVID-19 remains the main mitigating factor in preventing its progression. Oral antiviral therapies offer a convenient outpatient treatment option for mild-moderate COVID-19, and when used early may decrease the risk of progression of disease. Oral anti-viral therapies retain activity against all the currently known viral variants. Early diagnosis with prompt treatment and monitoring for drug-drug interactions is the key to optimal use of oral antiviral agents for COVID-19. Despite the promise to decrease morbidity and mortality from COVID-19, utilization of these medications among SOTRs remains low with existence of many barriers in their use.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, antivirals, treatment, coronavirus, oral, organ transplant, molnupiravir, nirmatrelvir, remdesivir, ensitrelvir, mindeudesivir, simnotrelvir
Abbreviations : COVID-19, SARS-CoV-2, SOTR, FDA, RNA
Plan
| Funding: There is no funding for this work. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.